AI predicts mutations underlying neurological diseases
Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
F2G bags 50.8m financing to advance olorofim
/in News/by Thomas GabrielczykUK-Austrian fungal infection specialist F2G Ltd has secured a 50.8m (US $60.8m) financing from new and existing investors.
Evotec receives $8.4m CARB-X funding
/in News/by Thomas GabrielczykEvotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
/in News/by Thomas GabrielczykBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
/in News/by Thomas GabrielczykEvotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
EC secures 300 million doses of COVID-19 vaccine
/in News/by Thomas GabrielczykThe European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine.
Roche’s IL-6 receptor blocker fails in Phase III
/in News/by Thomas GabrielczykRoche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Enthera Pharmaceuticals Srl raises 28m in Series A financing
/in News/by Thomas GabrielczykItalian start-up Enthera Pharmaceuticals has raised 28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Polyphor AG bags CHF19.3 in equity financing
/in News/by Thomas GabrielczykSwiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
COVID-19: Siemens assay outperforms antibody tests from competitors
/in News/by Thomas GabrielczykIn a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.